These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Immunosuppression during viral oncogenesis. V. Resistance to virus-induced immunosuppressive factor. Strayer DS; Dombrowski J J Immunol; 1988 Jul; 141(1):347-51. PubMed ID: 2837511 [TBL] [Abstract][Full Text] [Related]
15. Interactions of murine leukemia virus (MuLV) with isolated lymphocytes. II. Infections of B and T cells with Friend virus complex indiffusion chambers and in vitro: effect of polyclonal mitogens. Cerny J; Hensgen PA; Fistel SH; Demler LM Int J Cancer; 1976 Aug; 18(2):189-96. PubMed ID: 1085288 [TBL] [Abstract][Full Text] [Related]
16. Malignant rabbit fibroma virus: observations on the culture and histopathologic characteristics of a new virus-induced rabbit tumor. Strayer DS; Cabirac G; Sell S; Leibowitz JL J Natl Cancer Inst; 1983 Jul; 71(1):91-104. PubMed ID: 6306326 [TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of immunosuppression induced by virus replication in lymphocytes. Heard HK; O'Connor K; Strayer DS J Immunol; 1990 May; 144(10):3992-9. PubMed ID: 2159037 [TBL] [Abstract][Full Text] [Related]
18. Determinants of the ability of malignant fibroma virus to induce immune dysfunction and tumor dissemination in vivo. Strayer DS; Laybourn KA; Heard HK Microb Pathog; 1990 Sep; 9(3):173-89. PubMed ID: 1964998 [TBL] [Abstract][Full Text] [Related]
19. Further characterization of Marek's disease virus-infected lymphocytes. II. In vitro infection. Calnek BW; Schat KA; Ross LJ; Chen CL Int J Cancer; 1984 Mar; 33(3):399-406. PubMed ID: 6321365 [TBL] [Abstract][Full Text] [Related]
20. Further characterization of Marek's disease virus-infected lymphocytes. I. In vivo infection. Calnek BW; Schat KA; Ross LJ; Shek WR; Chen CL Int J Cancer; 1984 Mar; 33(3):389-98. PubMed ID: 6321364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]